NCTN Trial Portfolios

Note: For full functionality, it is recommended that users download the PDF file, and open with a PDF reader.

Cancer trials ordered by disease area:

• Brain (pdf)

• Breast (pdf)

• Gastrointestinal (pdf)

• Genitourinary (pdf)

• Gynecological (pdf)

• Head and Neck (pdf)

• Leukemia (pdf)

• Lymphoma (pdf)

• Myeloma (pdf)

• Sarcoma (pdf)

• Skin (Mainly Melanoma) (pdf)

• Thoracic (pdf)

• Endocrine/Neuroendocrine (pdf)

• Adolescent and Young Adult (AYA) (pdf)

This portfolio shows NCTN trials. For information about NCORP trials, please see: https://ncorp.cancer.gov/find-a-study/ NCTN Brain Cancer Trials Portfolio (Open as of 9/15/2021) Each far right box includes the NCTN protocol number with a hyperlink to the associated ClinicalTrials.gov webpage. Click on it to view the protocol title and study information.

Craniopharyngioma A071601

Newly diagnosed NRG-BN001

High Grade (Grade Newly diagnosed, MGMT IV) Glioma - Unmethylated, No IDH NRG-BN007 Glioblastoma mutation (GBM) A071702

Recurrent EAF151 NRG-BN010 1p/19q Co-deletion, Low and N0577 (CODEL) Intermediate Anaplastic or low grade

Brain Grade (Grade II and IDH Mutant, Low and NRG-BN005 III) Glioma intermediate grade

Gross totally resected, Grade II NRG-BN003 Meningioma SMO/AKT/NF2 mutated, A071401 Progressive

5-15 brain metastases CCTG CE.7 Presence of alteration in NTRK, A071701 ROS1, CDK or PI3K pathway Metastases to Brain 3 or fewer unresected brain A071801 metastases post-resection First or second distant brain NRG-BN009 relapse after upfront SRS

Cross-disease trials:

EAY131 (MATCH) S1609 (DART) NCTN Brain Cancer Trials (Open as of 9/15/2021)

Protocol Number Phase Protocol Title Phase II Trial of SMO/ AKT/ NF2 Inhibitors in Progressive Meningiomas with SMO/ AKT/ NF2 A071401 II Mutations A071601 II Phase II Trial of BRAF/MEK Inhibitors in Papillary Craniopharyngiomas A071701 II Genomically‐Guided Treatment Trial in Brain Metastases A Phase II Study of Checkpoint Blockade Immunotherapy in Patients with Somatically Hypermutated A071702 II Recurrent Glioblastoma Phase III Trial of Post‐Surgical Single Fraction Stereotactic Radiosurgery (SRS) Compared with A071801 III Fractionated SRS (FSRS) for Resected Metastatic Brain Disease A Phase III Trial of Stereotactic Radiosurgery Compared with Whole Brain Radiotherapy (WBRT) for 5‐ CCTG CE.7 III 15 Brain Metastases Change in Relative Cerebral Blood Volume as a Biomarker for Early Response to Bevacizumab in EAF151 II Patients with Recurrent Glioblastoma N0577 (CODEL): Phase III Intergroup Study of Radiotherapy with Concomitant and Adjuvant Temozolomide versus Radiotherapy with Adjuvant PCV Chemotherapy in Patients with 1p/19q Co‐ N0577 III deleted Anaplastic Glioma or Low Grade Glioma Randomized Phase II Trial of Hypofractionated Dose‐Escalated Photon IMRT or Proton Beam Therapy Versus Conventional Photon Irradiation with Concomitant and Adjuvant Temozolomide in Patients NRG‐BN001 II with Newly Diagnosed Glioblastoma

NRG‐BN003 III Phase III Trial of Observation Versus Irradiation for a Gross Totally Resected Grade II Meningioma A Phase II Randomized Trial of Proton Vs. Photon Therapy (IMRT) for Cognitive Preservation in NRG‐BN005 II Patients with IDH Mutant, Low to Intermediate Grade Gliomas A Randomized Phase II/III Open‐Label Study of Ipilimumab and Nivolumab Versus Temozolomide in Patients with Newly Diagnosed MGMT (Tumor O‐6‐Methylguanine DNA Methyltransferase) NRG‐BN007 II/III Unmethylated Glioblastoma Phase III Trial of Salvage Stereotactic Radiosurgery (SRS) or SRS + Hippocampal‐Avoidant Whole Brain Radiotherapy (HA‐WBRT) for First or Second Distant Brain Relapse After Upfront SRS with Brain NRG‐BN009 III Metastasis Velocity >/= 4 Brain Metastases/Year A Safety Run‐In and Phase II Study Evaluating the Efficacy, Safety, and Impact on the Tumor Microenvironment of the Combination of Tocilizumab, Atezolizumab, and Fractionated Stereotactic NRG‐BN010 II Radiotherapy in Recurrent Glioblastoma EAY131 II Molecular Analysis for Therapy Choice (MATCH) S1609 II DART: Dual Anti‐CTLA‐4 and Anti‐PD‐1 Blockade in Rare Tumors

This portfolio shows NCTN trials. For information about NCORP trials, please see: https://ncorp.cancer.gov/find‐a‐study/ Click on trial number to go to the associated ClinicalTrials.gov NCTN Breast Cancer Trials Portfolio (Open as of 9/15/2021) webpage, to view the protocol title and study information. Neoadjuvant Post‐Neoadjuvant Adjuvant Metastatic

EAI142 EA1181 HR+/HER2‐ NRG‐BR005 NRG‐BR003 [18F] Fluoroestradiol PET study (COMPASS‐pCR) Any HR/HER2 status TNBC HER2+ Stage II and IIIa NRG‐BR002 Any HR/HER2 status S1706 Female only; No brain mets Any HR/HER2 status CCTG MA.39 Inflammatory; No mets HR+/HER2‐ Low risk; Node positive EA1183 (FEATURE) HR+ Bone‐dominant (BD) or bone‐only A011202 (BO) disease Any HR/HER2 status NRG‐BR007 Surgery (Intra‐Operative) NRG‐BR004 (DEBRA) HER2+ HR+/HER2‐ 1st line; Some brain mets allowed pT1(<=2cm) pN0M0 A011801 (COMPASS‐RD) HER2+ S2007 T1‐4, N0‐3 HER2‐ Any HR‐; If HR+, node+ Brain metastases

EAY131 (MATCH)

S1609 (DART)

Legend by Subtype Status White = Blue = HER2‐ Orange = HER2+ Purple = Yellow = HR+ Pink = Cross‐ Any HR/HER2 Green = TNBC (Any HR status) (Any HR status) HR+ and HER2‐ (Any HER2 status) disease trials status NCTN Breast Cancer Trials (Open as of 9/15/2021)

Protocol Number Phase Protocol Title A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1‐3 N1) Who Have A011202 III Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy The COMPASSHER2 Trials (COMprehensive Use of Pathologic Response ASSessment to Optimize Therapy in HER2‐Positive Breast Cancer): COMPASSHER2 Residual Disease (RD), A Double‐Blinded, Phase III Randomized Trial of T‐DM1 and Placebo Compared with T‐DM1 and A011801 III Tucatinib CCTG MA.39 III Tailor RT: A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive Breast Cancer EA1181 (CompassHER2‐pCR): Preoperative THP and Postoperative HP in Patients Who Achieve a Pathologic Complete Response Part 1 Component of: The CompassHER2 Trials (COMprehensive Use of Pathologic Response ASSessment to Optimize Therapy in HER2‐ EA1181 II Positive Breast Cancer) EA1183 II FDG PET to Assess Therapeutic Response in Patients with Bone‐Dominant Metastatic Breast Cancer, FEATURE

EAI142 II [18F] Fluoroestradiol (FES) PET as a Predictive Measure for Endocrine Therapy in Patients with Newly Diagnosed Metastatic Breast Cancer A Phase IIR/III Trial of Standard of Care Therapy with or Without Stereotactic Body Radiotherapy (SBRT) and/or Surgical Ablation for Newly NRG‐BR002 II/III Oligometastatic Breast Cancer A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or NRG‐BR003 III Without Carboplatin for Node‐Positive or High‐Risk Node‐Negative Triple‐Negative Invasive Breast Cancer A Randomized, Double‐Blind, Phase III Trial of Paclitaxel/Trastuzumab/Pertuzumab with Atezolizumab or Placebo in First‐Line HER2‐Positive NRG‐BR004 III Metastatic Breast Cancer

A Phase II Trial Assessing the Accuracy of Tumor Bed Biopsies in Predicting Pathologic Response in Patients with Clinical/Radiologic Complete NRG‐BR005 II Response After Neoadjuvant Chemotherapy in Order to Explore the Feasibility of Breast Conserving Treatment Without Surgery A Phase III Clinical Trial Evaluating De‐Escalation of Breast Radiation for Conservative Treatment of Stage I, Hormone Sensitive, HER2‐Negative, NRG‐BR007 III Oncotype Recurrence Score

S2007 II A Phase II Trial of Sacituzumab Govitecan (IMMU‐132) (NSC #820016) for Patients with HER2‐Negative Breast Cancer and Brain Metastases EAY131 II Molecular Analysis for Therapy Choice (MATCH) S1609 II DART: Dual Anti‐CTLA‐4 and Anti‐PD‐1 Blockade in Rare Tumors

This portfolio shows NCTN trials. For information about NCORP trials, please see: https://ncorp.cancer.gov/find‐a‐study/ Gastrointestinal ClinicalTrials.gov webpage.Clickonit Each farrightboxincludestheNCTN protocolnumberwithahyperlinktotheassociated NCTN GastrointestinalCancerTrialsPortfolio(Open asof9/15/2021) carcinoma of carcinoma of Adenocarcinoma Adenocarcinoma esophageal esophageal cancers of the pancreas theof Anal cancer Anal the rectum Adedo Colorectal Biliary Biliary Hepatocellular carcinoma Hepatocellular the colon the Gastro- tract cancer Adeno Adeno cancer small intestinesmall - carcinoma theof - - bladder cancerbladder Metastatic or Unresectable or Metastatic Incidental gall Adenocarcinoma or Newly diagnosed, Post diagnosed, Newly Deficient DNA MismatchRepair, Stage IV Adenocarcinoma - HER Inoperbale, recurrent,Inoperbale, untreatedor metastatic StageIII, MSIII or - Deficient DNA MismatchRepair, Stage III Stage T1 Stage Squamous cell cell Squamous Metastatic,BRCA1/BRCA2 mutation, maintenance Resected carcinoma Newly diagnosed, resectable, Tx diagnosed, Newly No dMMR or MSI or dMMR No with at least SD with platinum at least with with SD Metastatic, untreated patients) (Elderly 2 Amplification2 Adenocarcinoma Advanced/Metastatic - 2N0M0, Tumor2N0M0, <=4cm , aBRCA1, BRCA2 or PALB2 mutation to view the protocol title andstudyinformation. title toviewthe protocol Metastaticor locally T 2 or T3 disease, postdisease, or T3 2 Proton Photonvs. H or dMMR or H cholecystectomy advanced - - resection, Stage IIA H disease, H disease, - non advanced, Locally No T4b, no no metastatic T4b, No Oligometastatic, HER2 surgery candidate Newly diagnosed, diagnosed, Newly Progressed locoregional negative disease - based therapybased - 4, N0- 4, EA2201 EA2182 (DECREASE) 1, M0 1, A021703 (SOLARIS) EA2197 (OPT S1922 NRG S1613 NRG A021502 (ATOMIC) NRG EA2187 EA2192 (APOLLO) EA2186 (GIANT) - GI004 (COMMIT) - GI005 (COBRA) EA2176 -GI003 A021806 NRG NRG EA2183 EA2174 S2001 - IN) -GI006 -GI007 NCTN Gastrointestinal Cancer Trials Portfolio (Open as of 9/15/2021) Each far right box includes the NCTN protocol number with a hyperlink to the associated ClinicalTrials.gov webpage. Click on it to view the protocol title and study information.

Locally Pancreatic or advanced/unresectable or A021602 Gastrointestinal metastatic; Progressed (CABINET) Neuroendocrine Tumors disease Gastrointestinal

Cross-disease trials:

EAY131 (MATCH) S1609 (DART) NCTN Gastrointestinal Cancer Trials (Open as of 9/15/2021)

Protocol Number Phase Protocol Title Randomized Trial of Standard Chemotherapy Alone or Combined with Atezolizumab as Adjuvant Therapy for A021502 III Patients with Stage III Colon Cancer and Deficient DNA Mismatch Repair Randomized, Double‐Blinded Phase III Study of CABozantinib Versus Placebo IN Patients with Advanced A021602 III NEuroendocrine Tumors After Progression on Everolimus (CABINET) Randomized Double‐Blind Phase III Trial of Vitamin D3 Supplementation in Patients with Previously Untreated A021703 III Metastatic Colorectal Cancer (SOLARIS) A021806 III A Phase III Trial of Perioperative Versus Adjuvant Chemotherapy for Resectable Pancreatic Cancer A Phase II/III Study of Peri‐Operative Nivolumab and Ipilimumab in Patients with Locoregional Esophageal and EA2174 II/III Gastroesophageal Junction Adenocarcinoma A Randomized Phase III Study of Immune Checkpoint Inhibition with Chemotherapy in Treatment‐Naïve EA2176 III Metastatic Anal Cancer Patients A Randomized Phase II Study of De‐Intensified ChemoRadiation for Early‐Stage Anal Squamous Cell EA2182 II Carcinoma (DECREASE) A Phase III Study of Consolidative Radiotherapy in Patients with Oligometastatic HER2 Negative Esophageal EA2183 III and Gastric Adenocarcinoma (EGA)

A Randomized Phase II Study of Gemcitabine and Nab‐Paclitaxel Compared with 5‐Fluorouracil, Leucovorin, EA2186 II and Liposomal Irinotecan in Older Patients with Treatment Naïve Metastatic Pancreatic Cancer (GIANT) A Phase 2 Study of Pevonedistat in Combination with Carboplatin and Paclitaxel in Advanced Intrahepatic EA2187 II Cholangiocarcinoma APOLLO: A Randomized Phase II Double‐Blind Study of Olaparib Versus Placebo Following Adjuvant Chemotherapy in Patients with Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 EA2192 II Mutation

EA2197 II/III Optimal Perioperative Therapy for Incidental Gallbladder Cancer (OPT‐IN): A Randomized Phase II/III Trial A Phase II Study of Neoadjuvant Nivolumab Plus Ipilimumab and Short‐Course Radiation in MSI‐H/dMMR EA2201 II Locally Advanced Rectal Adenocarcinoma NRG‐GI003 III A Phase III Randomized Trial of Protons Versus Photons for Hepatocellular Carcinoma Colorectal Cancer Metastatic dMMR Immuno‐Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab Combination Chemotherapy with or Without Atezolizumab or Atezolizumab Monotherapy in the First‐Line Treatment of Patients with Deficient DNA Mismatch Repair (dMMR) NRG‐GI004 III Metastatic Colorectal Cancer Phase II/III Study of Circulating Tumor DNA as a Predictive Biomarker in Adjuvant Chemotherapy in Patients NRG‐GI005 II/III with Stage IIA Colon Cancer (COBRA) Phase III Randomized Trial of Proton Beam Therapy (PBT) Versus Intensity Modulated Photon Radiotherapy NRG‐GI006 III (IMRT) for the Treatment of Esophageal Cancer

Phase I Trial with Expansion Cohort of OBP‐301 (Telomelysin) and Definitive Chemoradiation for Patients with NRG‐GI007 I Locally Advanced Esophageal and Gastroesophageal Adenocarcinoma Who Are Not Candidates for Surgery A Randomized Phase II Study of Trastuzumab and Pertuzumab (TP) Compared to Cetuximab and Irinotecan S1613 II (CETIRI) in Advanced/Metastatic Colorectal Cancer (MCRC) with HER‐2 Amplification Randomized Phase II Selection Study of Ramucirumab and Paclitaxel Versus FOLFIRI in Refractory Small S1922 II Bowel Adenocarcinoma Randomized Phase II Clinical Trial of Olaparib + Pembrolizumab vs. Olaparib Alone as Maintenance Therapy in S2001 II Metastatic Pancreatic Cancer Patients with Germline BRCA1 or BRCA2 Mutations EAY131 II Molecular Analysis for Therapy Choice (MATCH) S1609 II DART: Dual Anti‐CTLA‐4 and Anti‐PD‐1 Blockade in Rare Tumors

This portfolio shows NCTN trials. For information about NCORP trials, please see: https://ncorp.cancer.gov/find‐a‐study/ Genitourinary andstudyinformation. title toviewthe protocol ClinicalTrials.gov webpage.Clickonit Each farrightboxincludestheNCTN protocolnumberwithahyperlinktotheassociated NCTN GenitourinaryCancerTrialsPortfolio(Openasof9/15/2021) Prostate Prostate carcinoma tract/Bladder Rare GU Germ cell Renal cell cancers cancer cancer Urothelial Upper tractcarcinoma urothelialUpper Penile carcinoma squamous cancer Metastatic disease Progressive or Recurrent PostProstatectomy, of Undetectablerisk High PSA, Localized,Previously untreated, Intermediate risk TFE/translocation, Unresectablemetastatic or Previouslyuntreated, Non- risk, High At least two untreated metastasesbone Post Prostatectomy, positive,Node disease M0 Metastatic, Untreatedtreated or Non PostProstatectomy, Biochemicalrecurrence Muscle invasive Newly diagnosed, Surgical Txindicated - Muscle invasive Metastatic, Untreated Metastatic, Previouslyuntreated, Metastatic Metastatic, Castration PostProstatectomy, risk High A031702 metastasis Any T,N1 Locally advanced or metastatic Newly diagnosed, High gradeHigh Any T,N1 T2 BCG Localized Metastatic -4a,N0/x,M0 AYA(Age>=14) Study - resistant -Unresponsive - 3, M0 3, - 2, M0 2, metastatic EA8192 A031704 (PDIGREE) A031704 S1931 (PROBE)S1931 A031801 (RadiCa S1806 EA8185 (INSPIRE) A031701 EA8134 (InPACT) S1937 AREN1721 A031803 A031102 (TIGER) A031102 (ERADICATE) NRG NRG NRG NRG (PREDICT- NRG (CASPAR) EA8171 A031902 A031902 EA8183 EA8191 S1802 -GU005 -GU007 -GU002 -GU008 -GU009 A031901 L) RT) NCTN Genitourinary Cancer Trials Portfolio (Open as of 9/15/2021) Each box below includes the NCTN protocol number with a hyperlink to the associated ClinicalTrials.gov webpage. Click on it to view the protocol title and study information.

Cross-disease trials:

EAY131 (MATCH) S1609 (DART) NCTN Genitourinary Cancer Trials (Open as of 9/15/2021)

Protocol Number Phase Protocol Title A Randomized Phase III Trial Comparing Conventional‐Dose Chemotherapy Using Paclitaxel, Ifosfamide, and Cisplatin (TIP) with High‐Dose Chemotherapy Using Mobilizing Paclitaxel Plus Ifosfamide Followed by High‐Dose Carboplatin A031102 III and Etoposide (TI‐CE) as First Salvage Treatment in Relapsed or Refractory Germ Cell Tumors A Phase II Study of Dose‐Dense Gemcitabine Plus Cisplatin (ddGC) in Patients with Muscle‐Invasive Bladder Cancer with Bladder Preservation for Those Patients Whose Tumors Harbor Deleterious DNA Damage Response (DDR) Gene A031701 II Alterations A031702 II Phase II Study of Cabozantinib in Combination with Nivolumab and Ipilimumab in Rare Genitourinary Tumors PD‐Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab Vs. VEGF TKI Cabozantinib with Nivolumab: A Phase A031704 III III Trial in Metastatic Untreated REnal Cell CancEr [PDIGREE] A Phase II Randomized Trial of Radium‐223 Dichloride and Cabozantinib in Patients with Advanced Renal Cell A031801 II Carcinoma with Bone Metastasis (RadiCal) Phase II Trial of Intravesical Gemcitabine and MK‐3475 (Pembrolizumab) in the Treatment of Patients with BCG‐ A031803 II Unresponsive Non‐Muscle Invasive Bladder Cancer Duration of Immune Checkpoint Therapy in Locally Advanced or Metastatic Urothelial Carcinoma: A Randomized A031901 III Phase 3 Non‐Inferiority Trial CASPAR ‐ A Phase III Trial of Enzalutamide and Rucaparib as a Novel Therapy in First‐Line Metastatic Castration‐ A031902 III Resistant Prostate Cancer A Randomized Phase 2 Trial of Axitinib/Nivolumab Combination Therapy vs. Single Agent Axitinib or Nivolumab for AREN1721 II the Treatment of TFE/Translocation Renal Cell Carcinoma (tRCC) Across All Age Groups EA8134 III InPACT‐ International Penile Advanced Cancer Trial (International Rare Cancers Initiative Study) Multiparametric MRI (mpMRI) for Preoperative Staging and Treatment Planning for Newly‐Diagnosed Prostate EA8171 II Cancer A Phase III Double Blinded Study of Early Intervention After RADICAl ProstaTEctomy with Androgen Deprivation Therapy with Darolutamide vs. Placebo in Men at Highest Risk of Prostate Cancer Metastasis by Genomic EA8183 III Stratification (ERADICATE) Phase 2 Study of Bladder‐SparIng ChemoradiatioN with MEDI4736 (Durvalumab) in Clinical Stage 3, Node PosItive EA8185 II BladdeR CancEr (INSPIRE) Phase III Study of PET‐Directed Local or Systemic Therapy Intensification in Prostate Cancer Patients with Post‐ EA8191 III Prostatectomy Biochemical Recurrence A Phase II/III Trial of MED14736 (Durvalumab) and Chemotherapy for Patients with High Grade Upper Tract EA8192 II/III Urothelial Cancer Prior to Nephroureterectomy Phase II‐III Trial of Adjuvant Radiotherapy and Androgen Deprivation Following Radical Prostatectomy with or NRG‐GU002 II/III Without Adjuvant Docetaxel NRG‐GU005 III Phase III IGRT and SBRT Vs IGRT and Hypofractionated IMRT for Localized Intermediate Risk Prostate Cancer Randomized Phase II Trial of Niraparib with Standard Combination Radiotherapy and Androgen Deprivation Therapy NRG‐GU007 II (ADT) in High Risk Prostate Cancer (with Initial Phase I) Randomized Phase III Trial Incorporating Abiraterone Acetate with Prednisone and Apalutamide and Advanced NRG‐GU008 III Imaging Into Salvage Treatment for Patients with Node‐Positive Prostate Cancer After Radical Prostatectomy Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De‐Intensification for Lower Genomic NRG‐GU009 III Risk and Intensification of Concurrent Therapy for Higher Genomic Risk with Radiation (PREDICT‐RT*) Phase III Randomized Trial of Standard Systemic Therapy (SST) Versus Standard Systemic Therapy Plus Definitive S1802 III Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer Phase III Randomized Trial of Concurrent Chemoradiotherapy with or Without Atezolizumab in Localized Muscle S1806 III Invasive Bladder Cancer Phase III Trial of Immunotherapy‐Based Combination Therapy with or Without Cytoreductive Nephrectomy for S1931 III Metastatic Renal Cell Carcinoma (PROBE Trial) A Phase III Randomized Trial of Eribulin (NSC #707389) with or Without Gemcitabine Versus Standard of Care (Physician's Choice) for Treatment of Metastatic Urothelial Carcinoma Refractory to, or Ineligible for, Anti PD1/PDL1 S1937 III Therapy EAY131 II Molecular Analysis for Therapy Choice (MATCH) S1609 II DART: Dual Anti‐CTLA‐4 and Anti‐PD‐1 Blockade in Rare Tumors

This portfolio shows NCTN trials. For information about NCORP trials, please see: https://ncorp.cancer.gov/find‐a‐study/ ClinicalTrials.gov webpage. Click on it to view the protocol title andstudyinformation. title toviewthe protocol ClinicalTrials.gov webpage.Clickonit Each farrightboxincludestheNCTN protocolnumberwithahyperlinktotheassociated Trials Portfolio(Open asof9/15/2021) NCTN GynecologicCancer Gynecologic Ovarian Trophoblastic Vulva cancer cancer (sq, adeno, (sq, adeno sq) adeno Cervical Cervical Uterine Vaginal tumors cancer cancer cancer (scc) Epithelial Germ cell Tumor diameter Newly diagnosed, diagnosed, Newly Newly diagnosed, diagnosed, Newly Newly diagnosed, diagnosed, Newly Locally advanced Locally Locally advanced Locally Organ confined, Unifocal T1, StageIII/IV or Recurrent Recurrent recurrent High risk High Stage I/II < 4cm Recurrent Intermediate and poor risk Intermediate risk poor and Newly diagnosed Newly Low metastatic metastatic - standard risk 1 SN with metastasiswith SN1 2mm ≤ node: > 2mm, or more> 2mm, node: than Metastatic lymph sentinel Endometrioid or or Endometrioid S1609 (DART) Endometrioid Platinum Platinum Any histology sensitive resistant High intermediateHigh risk, NRG RTOG NRG GOG Deficient Mismatch Clear cell Clear Repair (dMMR) -GY006 -GY018 -0263 -0724 Low grade serous *: Currently link t Cell, and and othersCell, w BRCA mutation histology SOC/EOC/Clear BRCA mutation and others and w All HGS/EOC,All AGCT1531 AGCT1532 All All All HG HG All NRG NRG NRG -GY014 -GY012 -GY014 NRG o NRG website. NRG NRG NRG-GY024* -GY009 -GY020 -GY019 GY021 NRG GY023 NRG - - NCTN Gynecologic Cancer Trials Portfolio (Open as of 9/15/2021) Each box below includes the NCTN protocol number with a hyperlink to the associated ClinicalTrials.gov webpage. Click on it to view the protocol title and study information.

Cross-disease trials:

EAY131 (MATCH) S1609 (DART) NCTN Gynecologic Cancer Trials (Open as of 9/15/2021)

Protocol Number Phase Protocol Title A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. AGCT1531 III Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors A Randomized Phase 3 Trial of Accelerated Versus Standard BEP Chemotherapy for Patients with AGCT1532 III Intermediate and Poor‐Risk Germ Cell Tumors Randomized Phase III Clinical Trial of Adjuvant Radiation Versus Chemoradiation in Intermediate Risk, Stage I/IIA Cervical Cancer Treated with Initial Radical Hysterectomy and Pelvic GOG‐0263 III Lymphadenectomy (NCT #01101451) A Randomized Phase II Trial of Radiation Therapy and Cisplatin Alone or in Combination with Intravenous Triapine in Women with Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer NRG‐GY006 II of the Uterine Cervix or Stage II‐IVA Vaginal Cancer A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP‐Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin/Bevacizumab and CTEP‐Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin/Bevacizumab in Platinum Resistant NRG‐GY009 II/III Ovarian Cancer A Randomized Phase II Study Comparing Single‐Agent Olaparib, Single Agent Cediranib, and the Combination of Cediranib/Olaparib in Women with Recurrent, Persistent or Metastatic NRG‐GY012 II Endometrial Cancer A Phase II Study of Tazemetostat (EPZ‐6438) (IND # 138671) in Recurrent or Persistent Endometrioid or Clear Cell Carcinoma of the Ovary, and Recurrent or Persistent Endometrioid NRG‐GY014 II Endometrial Adenocarcinoma A Phase III Randomized, Placebo‐Controlled Study of Pembrolizumab (MK‐3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent NRG‐GY018 III Endometrial Cancer A Randomized Phase III, Two‐Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients with Stage II‐IV, Primary Low‐Grade Serous Carcinoma of the NRG‐GY019 III Ovary or Peritoneum A Phase III Randomized Trial of Radiation +/‐ MK‐3475 (Pembrolizumab) for Newly Diagnosed Early Stage High Intermediate Risk Mismatch Repair Deficient (dMMR) Endometrioid Endometrial NRG‐GY020 III Cancer A Phase II Randomized Trial of Olaparib Versus Olaparib Plus Tremelimumab in Platinum‐Sensitive NRG‐GY021 II Recurrent Ovarian Cancer A Randomized Phase II Trial of Triplet Therapy (A PD‐L1 Inhibitor Durvalumab (MEDI4736) in Combination with Olaparib and Cediranib) Compared to Olaparib and Cediranib or Durvalumab (MEDI4736) and Cediranib or Standard of Care Chemotherapy in Women with Platinum‐Resistant Recurrent Epithelial Ovarian Cancer, Primary Peritoneal or Fallopian Cancer Who Have Received NRG‐GY023 II Prior Bevacizumab Groningen International Study on Sentinel Nodes in Vulvar Cancer (GROINSS‐V) III: A Prospective NRG‐GY024 II Phase II Treatment Trial Phase III Randomized Study of Concurrent Chemotherapy and Pelvic Radiation Therapy with or without Adjuvant Chemotherapy in High‐Risk Patients with Early‐Stage Cervical Carcinoma RTOG‐0724 III Following Radical Hysterectomy S1609 II DART: Dual Anti‐CTLA‐4 and Anti‐PD‐1 Blockade in Rare Tumors EAY131 II Molecular Analysis for Therapy Choice (MATCH)

This portfolio shows NCTN trials. For information about NCORP trials, please see: https://ncorp.cancer.gov/find‐a‐study/ Head and Neck ClinicalTrials.gov webpage.Clickonit Each farrightboxincludestheNCTN CancerTrialsPortfolio(Openasof9/15/2021) NCTN HeadandNeck Lip and oral and Lip cavity carcinoma, NOS carcinoma, Nasopharyngeal Nasopharyngeal Head and neck neck and Head squamous cell cell squamous squamous cell cell squamous carcinoma carcinoma Untreated, unresected disease, Stage III PostsurgicalPathologic resection, stage pathologicfeatures, Pathologic stage III IVB (M0), Contraindicationto Cisplatin (M0), IVB Post surgical Locoregionally resection, Newly diagnosed, T1 diagnosed, Newly or IV (M0) ( (M0) IV or Detectable pretreatment plasma EBV Untreated,stage 3 Untreated,Early stage, P16 III IVAor III status (p53 required) (M0) recurrent (M0) or second primary primary second recurrent or (M0) DNA, Stage DNA, II Stageor N1 N0 or T4a with T3 Post risk surgicalHigh resection, disease, with high risk features risk high with disease, Intermediaterisk, P16 evidence of of distantevidence metastasis

Untreated, advanced, Locally protocol number with a hyperlink to the associated protocol numberwithahyperlinktotheassociated to viewthe protocol Oropharynx: p16 negative)p16 Oropharynx: Recurrentor metastatic Surgically resectable advanced (M0) EGFR statusrequired; For candidate - IVB disease with no no with disease IVB - 4 local 4 - 2N0M0, Surgical2N0M0,

- title andstudyinformation. title positive - regionally - positive positive - 3, - NRG NRG NRG NRG NRG RTOG NRG EA3163 EA3161 EA3191 EA3132 -HN005 -HN008 -HN004 -HN006 -HN007 -HN001 -1216 NCTN Head and Neck Cancer Trials Portfolio (Open as of 9/15/2021) Each box below includes the NCTN protocol number with a hyperlink to the associated ClinicalTrials.gov webpage. Click on it to view the protocol title and study information.

Cross-disease trials:

EAY131 (MATCH) S1609 (DART) NCTN Head and Neck Cancer Trials (Open as of 9/15/2021)

Protocol Number Phase Protocol Title Phase II Randomized Trial of Radiotherapy with or Without Cisplatin for Surgically Resected Squamous EA3132 II Cell Carcinoma of the Head and Neck (SCCHN) with TP53 Sequencing A Phase II/III Randomized Study of Maintenance Nivolumab Versus Observation in Patients with Locally EA3161 II/III Advanced, Intermediate Risk HPV Positive OPCA Phase II Randomized Trial of Neo‐Adjuvant Chemotherapy Followed by Surgery and Post‐Operative Radiation Versus Surgery and Post‐Operative Radiation for Organ Preservation of T3 and T4a Nasal and EA3163 II Paranasal Sinus Squamous Cell Carcinoma (NPNSCC) A Phase II Randomized Trial of Adjuvant Therapy with Pembrolizumab After Resection of EA3191 II Recurrent/Second Primary Head and Neck Squamous Cell Carcinoma with High Risk Features Randomized Phase II and Phase III Studies of Individualized Treatment for Nasopharyngeal Carcinoma NRG‐HN001 II/III Based on Biomarker Epstein Barr Virus (EBV) Deoxyribonucleic Acid (DNA) Randomized Phase II/III Trial of Radiotherapy with Concurrent MEDI4736 (Durvalumab) Vs. Radiotherapy with Concurrent Cetuximab in Patients with Stage III‐IVB Head and Neck Cancer with a Contraindication to NRG‐HN004 II/III Cisplatin A Randomized Phase II/III Trial of De‐Intensified Radiation Therapy for Patients with Early‐Stage, P16‐ NRG‐HN005 II/III Positive, Non‐Smoking Associated Oropharyngeal Cancer Randomized Phase II/III Trial of Sentinel Lymph Node Biopsy Versus Elective Neck Dissection for Early‐ NRG‐HN006 II/III Stage Oral Cavity Cancer An Open‐Label, Phase III Study of Platinum‐Gemcitabine with or Without Nivolumab in the First‐Line NRG‐HN007 III Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma

Phase I Trial with Expansion Cohort of DNA‐PK Inhibition and IMRT in Cisplatin‐Ineligible Patients with NRG‐HN008 I Stage 3‐4 Local‐Regionally Advanced Head and Neck Squamous Cell Carcinoma (HNSCC) Randomized Phase II/III Trial of Surgery and Postoperative Radiation Delivered with Concurrent Cisplatin Versus Docetaxel Versus Docetaxel and Cetuximab for High‐Risk Squamous Cell Cancer of the Head and RTOG‐1216 II/III Neck EAY131 II Molecular Analysis for Therapy Choice (MATCH) S1609 II DART: Dual Anti‐CTLA‐4 and Anti‐PD‐1 Blockade in Rare Tumors

This portfolio shows NCTN trials. For information about NCORP trials, please see: https://ncorp.cancer.gov/find‐a‐study/ Leukemia Clickonit webpage. ClinicalTrials.gov rightboxincludesthe Each far NCTN LeukemiaTrialsPortfolio(Openasof9/15/2021) leukemia (T leukemia (AML) leukemia (CML) precursor ALL) leukemia (ALL) leukemia (CLL) Acute myeloid Acute lymphoblastic lymphoblastic lymphoblastic lymphoblastic lymphoblastic lymphoblastic myelogenous myelogenous leukemia(B Precursor B Precursor T lymphocytic lymphocytic Chronic Chronic Chronic Chronic Acute Acute ALL) - cell - - - Relapsed or refractory or Relapsed

Relapsed or refractory or Relapsed Ph positive or Ph- or positive Ph NCTN a protocolnumberwith Newly diagnosed, Ph diagnosed, Newly chromosome positive chromosome Newly diagnosed, no no diagnosed, Newly Newly diagnosed or or diagnosed Newly relapsed/refractory Ph negative: Newly negative:Ph Newly Ph negativePh - ,CD22 meet indication for for indication meet Untreated disease, Newly diagnosed, diagnosed, Newly - CD22 activating FLT3activating Philadelphia Philadelphia diagnosed; diagnosed; treatment negative mutation positive positive to viewthe positive, Ph positive, like: protocol title and studyinformat protocoltitleand Ageyears ≥ 65 Ageyears ≥ 18 and < 40 years 40 < and Ageyears ≥ 18 and and Ageyears ≥ 18 Ageyears, ≥ 60 Ageyears, ≥ 18 Ageyears, ≥ 18 Ageyears ≥ 70 Ageyears ≥ 60 Ageyears ≥ 18 Ageyears ≥ 18 Relapsed or or Relapsed diagnosed refractory refractory High hyperlink to the associated hyperlinktotheassociated < Newly Newly 75 years75 - risk A041501 A041703 A041702 A041701 EA9181 EA9152 EA9171 S1318 S1905 S1712 S1925 ion. NCTN Leukemia Trials (Open as of 9/15/2021)

Protocol Number Phase Protocol Title A Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin (a Conjugated Anti‐ CD22 Monoclonal Antibody) to Frontline Therapy in Young Adults (Ages 18‐39 Years) with Newly A041501 III Diagnosed Precursor B‐Cell ALL A Randomized Phase II/III Study of Conventional Chemotherapy +/‐ Uproleselan (GMI‐1271) in Older Adults A041701 II/III with Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy

A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and A041702 III Obinutuzumab in Untreated Older Patients (>/= 70 Years of Age) with Chronic Lymphocytic Leukemia (CLL) A Phase II Study of Inotuzumab Ozogamicin Followed by Blinatumomab for Ph‐Negative, CD22‐Positive B‐ Lineage Acute Lymphoblastic Leukemia in Newly Diagnosed Older Adults or Adults with Relapsed or A041703 II Refractory Disease A Phase IB/II Study of Venetoclax (ABT‐199) in Combination with Liposomal Vincristine in Patients with EA9152 I/II Relapsed or Refractory T‐Cell or B‐Cell Acute Lymphoblastic Leukemia

Phase II Study of Adding the Anti‐PD‐1 Pembrolizumab to Tyrosine Kinase Inhibitors in Patients with EA9171 II Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease

A Phase III Randomized Trial of Steroids + Tyrosine Kinase Inhibitor Induction with Chemotherapy or EA9181 III Blinatumomab for Newly Diagnosed BCR‐ABL‐Positive Acute Lymphoblastic Leukemia in Adults

A Phase II Study of Blinatumomab (NSC‐765986) and POMP (Prednisone, Vincristine, Methotrexate, 6‐ Mercaptopurine) for Patients >/= 65 Years of Age with Newly Diagnosed Philadelphia‐Chromosome Negative (Ph‐) Acute Lymphoblastic Leukemia (ALL) and of Dasatinib (NSC‐732517), Prednisone and Blinatumomab for Patients >/= 65 Years of Age with Newly Diagnosed Philadelphia‐Chromosome Positive (Ph+) ALL, Relapsed/Refractory Philadelphia‐Chromosome Positive (Ph+) ALL, and Philadelphia‐ Chromosome‐Like Signature (Ph‐Like) ALL (Newly Diagnosed or Relapsed/Refractory) with Known or S1318 II Presumed Activating Dasatinib‐Sensitive Mutations or Kinase Fusions (DSMKF)

A Randomized Phase II Study of Ruxolitinib (NSC‐752295) in Combination with BCR‐ABL Tyrosine Kinase S1712 II Inhibitors in Chronic Myeloid Leukemia (CML) Patients with Molecular Evidence of Disease

This portfolio shows NCTN trials. For information about NCORP trials, please see: https://ncorp.cancer.gov/find‐a‐study/ NCTN Lymphoma Trials Portfolio (Open as of 9/15/2021) Each far right box includes the NCTN protocol number with a hyperlink to the associated ClinicalTrials.gov webpage. Click on it to view the protocol title and study information.

Relapsed or refractory A051301 Diffuse large Newly diagnosed, including MYC/BCL2 B-cell S1918 double-expressing and transformed lymphoma Inclduing MYC/BCL2 double-expressing A051701 High-grade Newly diagnosed, MYC/BCL2/BCL6 double or S1918 B-cell triple rearragement lymphoma A051701 Follicular Newly diagnosed, Grade IIIB S1918 lymphoma Relapsed or refractory S1608 Lymphoplasmacytic lymphoma Previously untreated S2005 (Waldenstrom macroglobulinemia) Untreated, with cyclin D1 (BCL1) EA4181 Mantle cell expression and/or t(11;14) lymphoma Evaluation of transplant & minimal residual EA4151 disease post initial induction therapy Lymphoma Previously untreated, Peripheral T-cell lymphoma A051902 CD30 negative Precursor T-lymphoblastic Relapsed or refractory S1905 lymphoma Chronic Lymphocytic Leukemia / Newly diagnosed, S1925 Small lymphocytic lymphoma Asymptomatic, High-risk Newly diagnosed, No evidence of Primary CNS lymphoma A051901 NHL outside CNS Classical Newly diagnosed, Untreated, Stage III/IV S1826 Hodgkin lymphoma Relapsed or refractory E4412

Cross-disease trial:

EAY131 (MATCH) NCTN Lymphoma Trials (Open as of 9/15/2021)

Protocol Number Phase Protocol Title A Randomized Double‐Blind Phase III Study of Ibrutinib During and Following Autologous Stem Cell Transplantation Versus Placebo in Patients with Relapsed or Refractory Diffuse Large B‐cell Lymphoma of A051301 III the Activated B‐cell Subtype Randomized Phase II/III Study of Venetoclax (ABT199) Plus Chemoimmunotherapy for MYC/BCL2 Double‐ A051701 II/III Hit and Double Expressing Lymphomas Phase I Trial of Methotrexate, Rituximab, Lenalidomide, and Nivolumab (Nivo‐MR2) Induction Followed by A051901 I Lenalidomide and Nivolumab Maintenance in Primary CNS Lymphoma A Randomized Phase II Study of CHO(E)P vs CC‐486‐CHO(E)P vs Duvelisib‐CHO(E)P in Previously Untreated A051902 II CD30 Negative Peripheral T‐Cell Lymphomas

A Phase I Study with an Expansion Cohort/Randomized Phase II Study of the Combinations of Ipilimumab, E4412 I/II Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Hodgkin Lymphoma A Randomized Phase III Trial of Consolidation with Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs Maintenance Rituximab Alone for Patients with Mantle Cell EA4151 III Lymphoma in Minimal Residual Disease‐Negative First Complete Remission A Randomized 3‐Arm Phase II Study Comparing 1.) Bendamustine, Rituximab and High Dose Cytarabine (BR/CR) 2.) Bendamustine, Rituximab, High Dose Cytarabine and Acalabrutinib (BR/CR‐A), and 3.) Bendamustine, Rituximab and Acalabrutinib (BR‐A) in Patients <= 70 Years Old with Untreated Mantle Cell EA4181 II Lymphoma S1608 II Randomized Phase II Trial in Early Relapsing or Refractory Follicular Lymphoma

A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus S1826 III AVD in Patients (Age >/= 12 Years) with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma

A Phase I/II Study of AKR1C3‐Activated Prodrug OBI‐3424 (OBI‐3424) In Patients with Relapsed/Refractory S1905 II T‐Cell Acute Lymphoblastic Leukemia (T‐ALL)/T‐Cell Lymphoblastic Lymphoma (T‐LBL) A Phase II/III Randomized Study of R‐MiniCHOP with or Without CC‐486 (Oral Azacitidine) in Participants Age 75 Years or Older with Newly Diagnosed Diffuse Large B Cell Lymphoma, Grade IIIB Follicular Lymphoma, Transformed Lymphoma, and High‐Grade B‐Cell Lymphomas with MYC AND BCL2 and/or S1918 II/III BCL6 Rearrangements

Randomized, Phase III Study of Early Intervention with Venetoclax and Obinutuzumab Versus Delayed Therapy with Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High‐Risk Patients with S1925 III Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): EVOLVE CLL/SLL Study A Phase II Randomized Study of Ibrutinib and Rituximab with or Without Venetoclax in Previously S2005 II Untreated Waldenström's Macroglobulinemia (WM) / Lymphoplasmacytic Lymphoma (LPL) EAY131 II Molecular Analysis for Therapy Choice (MATCH)

This portfolio shows NCTN trials. For information about NCORP trials, please see: https://ncorp.cancer.gov/find‐a‐study/ NCTN Myeloma Trials Portfolio (Open as of 9/15/2021) Each far right box includes the NCTN protocol number with a hyperlink to the associated ClinicalTrials.gov webpage. Click on it to view the protocol title and study information.

Newly diagnosed, Standard risk, Ineligible EAA181 (EQUATE) for autologous transplantation

Asymptomatic high-risk smoldering EAA173 disease without prior treatment (DETER-SMM)

Initial induction therapy for transplant eligible multiple myeloma or within 180 S1803 (DRAMMATIC) days of autotransplant completion Myeloma

Post autologous stem cell transplantation, on Lenalidomide maintenance (>=10mg EAA171 (OPTIMUM) daily dose) for at least 10 months and no more than 15 months; MRD+

Cross-disease trials:

EAY131 (MATCH) S1609 (DART) NCTN Myeloma Trials (Open as of 9/15/2021)

Protocol Number Phase Protocol Title EAA171 III Optimizing Prolonged Treatment In Myeloma Using MRD Assessment (OPTIMUM)

EAA173 III Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER‐SMM)

Effective Quadruplet Utilization After Treatment Evaluation (EQUATE): A Randomized Phase 3 Trial for EAA181 III Newly Diagnosed Multiple Myeloma Not Intended for Early Autologous Transplantation

Phase III Study of Daratumumab/rHuPH20 (NSC‐ 810307) + Lenalidomide or Lenalidomide as Post‐ Autologous Stem Cell Transplant Maintenance Therapy in Patients with Multiple Myeloma (MM) Using S1803 III Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC Study) EAY131 II Molecular Analysis for Therapy Choice (MATCH) S1609 II DART: Dual Anti‐CTLA‐4 and Anti‐PD‐1 Blockade in Rare Tumors

This portfolio shows NCTN trials. For information about NCORP trials, please see: https://ncorp.cancer.gov/find‐a‐study/ NCTN Sarcoma Trials Portfolio (Open as of 9/15/2021) Click on trial number to go to the associated ClinicalTrials.gov webpage, to view the protocol title and the study information. Newly Diagnosed Disease Recurrent Disease

Soft Tissue Sarcoma Soft Tissue Sarcoma ARST1431 A091902*

NRG-DT001^

Legend by Disease Types

Green = Soft Tissue Sarcoma ^: Only NRG participating *: COG not participating

Cross-disease trial:

EAY131 (MATCH) NCTN Sarcoma Trials (Open as of 9/15/2021)

Protocol Number Phase Protocol Title A Multicenter Phase II Trial of Paclitaxel with and Without Nivolumab in Taxane Naïve, and Nivolumab and Cabozantinib in Taxane A091902* II Pretreated Subjects with Angiosarcoma

A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating with Vincristine and Irinotecan (VI) ARST1431 III Versus VAC/VI Plus Temsirolimus (TORI, Torisel, NSC# 683864) in Patients with Intermediate Risk (IR) Rhabdomyosarcoma (RMS)

NRG‐DT001^ I A Phase Ib Trial of Neoadjuvant AMG‐232 Concurrent with Preoperative Radiotherapy in Wild‐Type P53 Soft Tissue Sarcoma (STS) EAY131 II Molecular Analysis for Therapy Choice (MATCH)

*: COG not participating ^: Only NRG participating

This portfolio shows NCTN trials. For information about NCORP trials, please see: https://ncorp.cancer.gov/find‐a‐study/ NCTN Skin Cancer Trials Portfolio (Open as of 9/15/2021) Each far right box includes the NCTN protocol number with a hyperlink to the associated ClinicalTrials.gov webpage. Click on it to view the protocol title and study information.

Resectable stage III BRAF V600 EA6183 B/C/D mutated

Resectable stage III with N2b-3c EA6194

Resectable stage III or IV S1801

BRAF wild-type or EA6141 mutated Melanoma BRAF V600 mutated EA6134 Unresectable stage III or IV BRAF V600E/K EA6191 mutated (BAMM2)

CR/PR/SD at 52 weeks EA6192 of anti-PD-1 therapy

Skin BRAF V600 Brain Metastases S2000 mutated

Merkel cell Completely resected, No EA6174 tumor metastatic disease (STAMP)

Squamous cell carcinoma Metastatic or locally A091802 of the skin advanced

Cross-disease trials:

EAY131 (MATCH) S1609 (DART) NCTN Skin Cancer Trials (Open as of 9/15/2021)

Protocol Number Phase Protocol Title Phase II Randomized Trial of Avelumab Plus Cetuximab Versus Avelumab Alone in Advanced Cutaneous A091802 II Squamous Cell Carcinoma of the Skin (cSCC) A Randomized Phase III Trial of Dabrafenib + Trametinib Followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab Followed by Dabrafenib + Trametinib at Progression in Patients EA6134 III with Advanced BRAFV600 Mutant Melanoma Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus EA6141 II/III Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma EA6174 III STAMP: Surgically Treated Adjuvant Merkel cell carcinoma with Pembrolizumab, a Phase III Trial A Phase II Neoadjuvant Study of Encorafenib with Binimetinib in Patients with Resectable Locoregional EA6183 II Metastases From Cutaneous or Unknown Primary Melanoma (Stages III N1B/C/D) The BAMM2 (BRAF, Autophagy, MEK Inhibition in Melanoma) Study: A Randomized Double Blind Phase II Study of Dabrafenib and Trametinib with or Without Hydroxychloroquine in Advanced BRAF V600E/K EA6191 II Melanoma A Phase II Study of Biomarker Driven Early Discontinuation of Anti‐PD‐1 Therapy in Patients with EA6192 II Advanced Melanoma (PET‐Stop) Phase II Randomized Study of Neoadjuvant Pembrolizumab Alone or in Combination with CMP‐001 in EA6194 II Patients with Operable Melanoma: Efficacy and Biomarker Study A Phase II Randomized Study of Adjuvant Versus NeoAdjuvant MK‐3475 (Pembrolizumab) for Clinically S1801 II Detectable Stage III‐IV High‐Risk Melanoma A Randomized Phase 2 Trial of Encorafenib + Binimetinib + Nivolumab Vs Ipilimumab + Nivolumab in S2000 II BRAF‐V600 Mutant Melanoma with Brain Metastases EAY131 II Molecular Analysis for Therapy Choice (MATCH) S1609 II DART: Dual Anti‐CTLA‐4 and Anti‐PD‐1 Blockade in Rare Tumors

This portfolio shows NCTN trials. For information about NCORP trials, please see: https://ncorp.cancer.gov/find‐a‐study/ Thoracic andstudyinformation. title toviewthe protocol ClinicalTrials.gov webpage.Clickonit Ea NCTN ThoracicCancerTrialsPortfolio(Open asof9/15/2021) ch farrightboxincludestheNCTN protocolnumberwithahyperlinktotheassociated cell lung lung cell Bronchial Neuroendocrine TumorsBronchial Neuroendocrine cancer Thymic carcinoma small small - Non Mesothelioma Small cell lung lung cell Small Lung or Thymus (Atypical)Thymus or Lung cancer carcinoid tumor Completely resected stage Stage IV, stage not amenableIIIB Superior sulcus tumorssulcus Superior Stage II IB IB 4cm), (≥ II or IIIA with stage IV recurrentor Previously-treated, sensitizing mutationsgenesensitizingALK and rearrangements Newly diagnosed, unresectable, stageunresectable, IIIA/B/C diagnosed, Newly - multi to definitive Stage IV, non - non Stage IV, non negative margin therapy,or recurrent - Newly diagnosed, T diagnosed, Newly III, with nonIII, with metastatic disease metastatic Extensivestage, SLFN11 positive (TPS ≥ 1%) 1%) positive≥ (TPS All stages,brain Mets All no Stage I Stage disease IV Unresectable, locally advanced, advanced, locally Unresectable, - squamous disease, PD disease, squamous - Extensive stage Extensive Squamous; NegativeSquamous; for EGFR TK1 Limited stage Limited s recurrent,or metastatic - operable, modality modality - IIIA, resectableIIIA, Progressed disease Screening Study Screening Resectable,M0 N0/1, cT3/T4, (ALCHEMIST 1-3 positive LUNGMAP - A151216 SCREEN) SSTR N 0 M 0 RTOG , high risk high , EGFR exon 20 sensitizing mutation - S1933 positive EGFR activating activating EGFR advanced/unresectable - L1 - or metastatic disease metastatic or Recurrent- locally or 1308 NRG NRG mutation - Non NRG S1827 (MAVERICK)S1827 KRAS G12C KRAS fusion positive fusion mutated EGFRALK and - - A021602 (CABINET) A021602 LU006 LU007(RAPTOR) - squamous, ALK ALK squamous, LU005 negative insertion S1929 NRG EA5163/S1709 (INSIGNA) - LU002 EA5181 S1701 S1914 S1934 (NASSIST)S1934 EA5191 S1900E EA5182 EA5162 A081801 A021901 E4512 NCTN Thoracic Cancer Trials Portfolio (Open as of 9/15/2021) Each box below includes the NCTN protocol number with a hyperlink to the associated ClinicalTrials.gov webpage. Click on it to view the protocol title and study information.

Cross-disease trials:

EAY131 (MATCH) S1609 (DART) NCTN Thoracic Cancer Trials (Open as of 9/15/2021)

Protocol Number Phase Protocol Title Randomized, Double‐Blinded Phase III Study of CABozantinib Versus Placebo IN Patients with Advanced A021602 III NEuroendocrine Tumors After Progression on Everolimus (CABINET) Randomized Phase II Trial of Lutetium Lu 177 Dotatate Versus Everolimus in Somatostatin Receptor Positive A021901 II Bronchial Neuroendocrine Tumors A081801 III Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo‐IO A151216 Other Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)

A Randomized Phase III Trial for Surgically Resected Early Stage Non‐Small Cell Lung Cancer: Crizotinib Versus E4512 III Observation for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein

EA5162 II Phase II Study of AZD9291 (Osimertinib) in Advanced NSCLC Patients with Exon 20 Insertion Mutations in EGFR EA5163/S1709 INSIGNA : A Randomized, Phase III Study of Firstline Immunotherapy Alone or in Combination with Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non‐Small Cell Lung EA5163 III Cancer (NSCLC) with Immunobiomarker SIGNature‐Driven Analysis Randomized Phase III Trial of MEDI4736 (Durvalumab) as Concurrent and Consolidative Therapy or Consolidative EA5181 III Therapy Alone for Unresectable Stage 3 NSCLC Randomized Phase III Study of Combination AZD9291 (Osimertinib) and Bevacizumab Versus AZD9291 (Osimertinib) Alone as First‐Line Treatment for Patients with Metastatic EGFR‐Mutant Non‐Small Cell Lung Cancer EA5182 III (NSCLC) A Randomized Phase II Trial of Cabozantinib and Cabozantinib Plus Nivolumab Versus Standard Chemotherapy in EA5191 II Patients with Previously Treated Non‐Squamous NSCLC A Master Protocol to Evaluate Biomarker‐Driven Therapies and Immunotherapies in Previously‐Treated Non‐Small LUNGMAP II Cell Lung Cancer (Lung‐MAP Screening Study) Maintenance Systemic Therapy Versus Consolidative Stereotactic Body Radiation Therapy (SBRT) Plus Maintenance Systemic Therapy for Limited Metastatic Non‐Small Cell Lung Cancer (NSCLC): A Randomized Phase NRG‐LU002 II/III II/III Trial Limited Stage Small Cell Lung Cancer (LS‐SCLC): A Phase II/III Randomized Study of Chemoradiation Versus NRG‐LU005 II/III Chemoradiation Plus Atezolizumab Phase III Randomized Trial of Pleurectomy/Decortication Plus Chemotherapy with or Without Adjuvant Hemithoracic Intensity‐Modulated Pleural Radiation Therapy (IMPRINT) For Malignant Pleural Mesothelioma NRG‐LU006 III (MPM) NRG‐LU007 II/III RAndomized Phase II/III Trial of Consolidation Radiation + Immunotherapy for ES‐SCLC: RAPTOR Trial Phase III Randomized Trial Comparing Overall Survival After Photon Versus Proton Chemoradiotherapy for RTOG‐1308 III Inoperable Stage II‐IIIB NSCLC A Randomized Phase II Trial of Carboplatin‐Paclitaxel with or Without Ramucirumab in Patients with Unresectable S1701 II Locally Advanced, Recurrent, or Metastatic Thymic Carcinoma A Randomized Phase III Trial of MRI Surveillance with or Without Prophylactic Cranial Irradiation (PCI) in Small‐Cell S1827 III Lung Cancer A Phase II Study of AMG 510 in Participants with Previously Treated Stage IV or Recurrent KRAS G12C Mutated S1900E II Non‐Squamous Non‐Small Cell Lung Cancer (ECOG‐ACRIN LUNG‐MAP SUB‐STUDY) A Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC #783608) + SBRT Versus SBRT Alone in S1914 III High Risk, Early Stage NSCLC Phase II Randomized Study of Maintenance Atezolizumab Versus Atezolizumab in Combination with Talazoparib in S1929 II Patients with SLFN11 Positive Extensive Stage Small Cell Lung Cancer (ES‐SCLC) A Pilot Study of Hypofractionated Radiotherapy Followed by Atezolizumab Consolidation in Stage II or III NSCLC S1933 II Patients with Borderline Performance Status NASSIST (Neoadjuvant Chemoradiation +/‐ Immunotherapy Before Surgery for Superior Sulcus Tumors): A Randomized Phase II Trial of Trimodality +/‐ Atezolizumab in Resectable Superior Sulcus Non‐Small Cell Lung S1934 II Cancer EAY131 II Molecular Analysis for Therapy Choice (MATCH) S1609 II DART: Dual Anti‐CTLA‐4 and Anti‐PD‐1 Blockade in Rare Tumors

Endocrine/ ch farrightboxincludestheNCTN protocolnumberwithahyperlinktotheassociated Neuroendocrine Adrenal or Adrenal or Thoracic Thoracic / GI trackGI adrenal Other or Unknown or Other Bronchi Extra - Thymus Pheochromocytoma receptor (SSTR) Lung or Paraganglioma Somatostatin Neuroendocrine Neuroendocrine Gastrointestinal Pancreatic or positive Tumors Atypical carcinoid Recurrent -advanced locally or Carcinoid or or Carcinoid /unresectableor metastatic Tumors or metastatic;or Progressed advanced/unresectable Metastatic or or Metastatic unresectable disease disease Locally Locally A021804 A021901 (CABINET) A021602

NCTN Endocrine/Neuroendocrine Cancer Trials (Open as of 9/15/2021)

Protocol Number Phase Protocol Title Randomized, Double‐Blinded Phase III Study of CABozantinib Versus Placebo IN Patients with A021602 III Advanced NEuroendocrine Tumors After Progression on Everolimus (CABINET) A Prospective, Multi‐Institutional Phase II Trial Evaluating Temozolomide vs. Temozolomide and A021804 II Olaparib for Advanced Pheochromocytoma and Paraganglioma Randomized Phase II Trial of Lutetium Lu 177 Dotatate Versus Everolimus in Somatostatin Receptor A021901 II Positive Bronchial Neuroendocrine Tumors

This portfolio shows NCTN trials. For information about NCORP trials, please see: https://ncorp.cancer.gov/find‐a‐study/ NCTN Adolescent to Young Adult (AYA) Cancer Trials Portfolio (Open as of 9/15/2021) Click on trial number to go to the associated ClinicalTrials.gov webpage, to view the protocol title and the study information. Newly Diagnosed Disease Recurrent Disease

Rhabdomyosarcoma (RMS) Germ Cell Tumors Germ Cell Tumors ARST1431 (Intermediate risk) AGCT1531 AGCT1532

ARST2031 (High risk) A031102 (TIGER) Adenocarcinoma of the colon Acute Lymphoblastic Leukemia A021502 (ATOMIC) Classical Hodgkin Lymphoma (ALL) A041501 Nongerminomatous germ cell E4412 tumor of the CNS Classical Hodgkin Lymphoma ACNS2021 Acute Lymphoblastic Leukemia S1826 (ALL) Mediastinal (thymic) large B‐cell AALL1821 TFE/Translocation Renal Cell lymphoma Carcinoma (tRCC) ANHL1931 AREN1721

Legend by Disease Types

Green = Yellow = Orange = Light Blue = Lime Green = Gray = Rhabdomyo‐ Germ Cell Blue = ALL Hodgkin Purple = tRCC Adenocarcinoma CNS NGGCT PMBCL sarcoma (RMS) Tumors Lymphoma of the colon

Cross‐disease trials EAY131 (MATCH) S1609 (DART)* NCICOVID (NCCAPS) *: COG not participating NCTN Adolescent to Young Adult (AYA) Cancer Trials (Open as of 9/15/2021)

Protocol Number Phase Protocol Title Randomized Trial of Standard Chemotherapy Alone or Combined with Atezolizumab as Adjuvant Therapy for Patients with Stage III A021502 III Colon Cancer and Deficient DNA Mismatch Repair A Randomized Phase III Trial Comparing Conventional‐Dose Chemotherapy Using Paclitaxel, Ifosfamide, and Cisplatin (TIP) with High‐ Dose Chemotherapy Using Mobilizing Paclitaxel Plus Ifosfamide Followed by High‐Dose Carboplatin and Etoposide (TI‐CE) as First A031102 III Salvage Treatment in Relapsed or Refractory Germ Cell Tumors A Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin (a Conjugated Anti‐CD22 Monoclonal Antibody) to A041501 III Frontline Therapy in Young Adults (Ages 18‐39 Years) with Newly Diagnosed Precursor B‐Cell ALL A Phase 2 Study of Blinatumomab (NSC# 765986) in Combination with Nivolumab (NSC # 748726), a Checkpoint Inhibitor of PD‐1, in B‐ AALL1821 II ALL Patients Aged >/= 1 to < 31 Years Old with First Relapse A Phase 2 Trial of Chemotherapy Followed by Response‐Based Whole Ventricular & Spinal Canal Irradiation (WVSCI) for Patients with ACNS2021 II Localized Non‐Germinomatous Central Nervous System Germ Cell Tumor A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and AGCT1531 III Adult Patients with Germ Cell Tumors A Randomized Phase 3 Trial of Accelerated Versus Standard BEP Chemotherapy for Patients with Intermediate and Poor‐Risk Germ Cell AGCT1532 III Tumors A Randomized Phase 3 Trial of Nivolumab (NSC# 748726) in Combination with Chemo‐Immunotherapy for the Treatment of Newly ANHL1931 III Diagnosed Primary Mediastinal B‐Cell Lymphoma A Randomized Phase 2 Trial of Axitinib/Nivolumab Combination Therapy vs. Single Agent Axitinib or Nivolumab for the Treatment of AREN1721 II TFE/Translocation Renal Cell Carcinoma (tRCC) Across All Age Groups A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating with Vincristine and Irinotecan (VI) ARST1431 III Versus VAC/VI Plus Temsirolimus (TORI, Torisel, NSC# 683864) in Patients with Intermediate Risk (IR) Rhabdomyosarcoma (RMS) A Randomized Phase 3 Trial of Vinorelbine, Dactinomycin, and Cyclophosphamide (VINO‐AC) Plus Maintenance Chemotherapy with Vinorelbine and Oral Cyclophosphamide (VINO‐CPO) vs Vincristine, Dactinomycin and Cyclophosphamide (VAC) Plus VINO‐CPO ARST2031 III Maintenance in Patients with High Risk Rhabdomyosarcoma (HR‐RMS) A Phase I Study with an Expansion Cohort/Randomized Phase II Study of the Combinations of Ipilimumab, Nivolumab and Brentuximab E4412 I/II Vedotin in Patients with Relapsed/Refractory Hodgkin Lymphoma A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 S1826 III Years) with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma EAY131 II Molecular Analysis for Therapy Choice (MATCH) NCICOVID Other NCI COVID‐19 in Cancer Patients Study (NCCAPS): A Longitudinal Natural History Study S1609* II DART: Dual Anti‐CTLA‐4 and Anti‐PD‐1 Blockade in Rare Tumors

*: COG not participating

This portfolio shows NCTN trials. For information about NCORP trials, please see: https://ncorp.cancer.gov/find‐a‐study/